| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Assertio Holdings (NASDAQ:ASRT) narrows FY2025 sales outlook from $108.000 million-$118.000 million to $110.000 million-$112.00...
Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $(0...
Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that its Board of Directo...
New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a sev...
Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive ...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and lowers the price...